Category Archives: Stem Cell Doctors


Hope for Emma’s voice: Child undergoes ground-breaking stem cell treatment – Stillwater News Press

DUNCAN, Okla. Emma Harper is closing out her summer with a ground-breaking stem cell treatment.

Cerebral Palsy and a Broad Spectrum Genetic Disorder create roadblocks in different forms for this 10-year-old Horace Mann student.

Her parents, Micah and Tara Harper, accompanied Emma on the trip to Orange, Calif., for the stem cell treatment if an effort to improve their daughter's life.

We never gave up hope that she would one day be able to speak, Micah said. We were told by doctors whenever she was much younger that she should probably be institutionalized, that she wouldnt walk, she wouldnt talk. She really has beat the odds. She can walk. She can walk on her own...

Emma continues to break through barriers in new and different ways.

Tuesday, Aug. 1, 2017, Emma and her parents met with Dr. Henderson, who is familiar with the Southwestern Oklahoma area, having been stationed at Fort Sill.

An initial meet and greet and question and answer portion of the procedure was completed. The Harpers were scheduled to go back the very next day for Emmas treatment, which usually lasts around two hours ended.

For Emma, whosebody accepted the vitamins and stem cells quickly, the treatment only took 20 to 30 minutes.

They (doctors) said whats happening is that her body is really accepting the stem cells. The doctor said that its like fireworks going off in her body right now, explained Micah. It was a really quick procedure, and the doctor said that within the next two weeks shes going to really start feeling the effects. We will see progress in two months, and she could continue making progress for two years.

There is no telling what type of progress Emma can expect.

Her body is dictating where the stem cells are going," Micah said.

Emmas doctor has seen miraculous recovery and progress in children with cerebral palsy. This treatment also has been used in early-onset dementia. The treatment has a 100 percent success rate with varying specific points of progress within the body.

While the Harpers cannot be completely sure this phenomenal treatment will give Emma her voice, other positives of the procedure could be highly beneficial.

It was a gamble that we were willing to take, Micah said.

Emma was feeling great and enjoyed sightseeing in Los Angeles Thursday after her treatment.

Arrington writes for The Duncan Banner, a CNHI News Service publication.

Read more:
Hope for Emma's voice: Child undergoes ground-breaking stem cell treatment - Stillwater News Press

Odessa physician offering stem cell therapy – Odessa American

An Odessa physician who specializes in pain management has begun offering stem cell therapy for inflammation from a variety of arthritis.

Dr. Mandeep Othee of ProCare Interventional Pain Medicine, said stem cell therapy has been around since as early as 1938. It has recently been used to stem inflammation, wound care and post-surgical use to help in healing.

The purpose for me is going to be for inflammation for knee arthritis, shoulder arthritis any sort of arthritic process in the neck, the back; any part of the body, Othee said.

Othee said hes always interested in cutting-edge treatments. As associate medical director of In-Patient Rehabilitation at Medical Center Hospital, Othee oversees care for patients with a variety of orthopedic needs, ranging from stroke patients to those recovering from joint replacement surgery, the hospital website said.

He also specializes in diagnosing and treating neck and low-back pain.

The source of the amniotic stem cells is healthy women who have had C-sections who donate their amniotic fluid to a tissue bank. Othee said it is fully regulated by the U.S. Food and Drug Administration and the cells are purified and frozen to preserve them.

The cells provide cushioning, support and lubrication to a developing fetus in the womb.

Its a similar process in the body, so for example, if we take that same stem cell and inject it into the patients knee, or shoulder, or back, or neck it provides the same cushioning, support, lubrication and inflammation reduction that it does in the developing fetus, Othee said.

He added that there are 226 growth factors in the fluid itself, which includes proteins, lipids electrolytes and the magic element of hyaluronic acid.

Thats the typical injection a patient receives in an orthopedic surgeons office. It basically heals the area, provides collagen synthesis and helps with the re-growth of that lost cartilage , Othee said.

Cartilage wears down over time in the joints and injecting the stem cells greatly increases the patients own healing response. Othee said it works 100,000 times better than Platelet Rich Plasma, which is taking a patients own platelets, spinning it down, putting it into a concentrated format and injecting into the patients knee, shoulder, neck or back, Othee said.

Typically, Othee said hes read studies have shown 30, 90 and 100-day responses that are better than steroid shots or hyaluronic acid injections.

It can help patients avoid or delay joint replacement surgeries.

The product he chose is OrthoFlo made by MiMedx.

I chose them because theyre the biggest and the best, Othee said. Their company specializes in different products. One is OrthoFlo. It contains pro-growth factors (and) no tissue fragments or dead cells. It is highly purified human amniotic fluid.

He noted that thousands of injections have been administered over the last five to 15 years and no reactions, side effects or infections have been reported that hes read about.

Currently, no insurance companies pay for the stem cell therapy, but athletes have been getting these for years in other countries, such as Germany and England, and larger cities such as Houston and Dallas. The cost is $2,200 per injection from Othee.

The patient may be sore for a day or two after the stem cell injection and they are able to walk out of the office without a problem. For any sort of knee injections, Othee said a patient may want to wait a week to start running or doing other activities.

Othee said he usually asks patients to stop taking anti-inflammatory medicine for at least seven days before and after the treatment.

He added that there is no age limit on people who could receive stem cell therapy.

Othee said patients may have tried steroid shots, hyaluronic acid, or platelet rich plasma before stem cell therapy. However, they could skip right to stem cell therapy, he added.

Othee said he has spoken to other doctors with patients who have gone straight to stem cell therapy and it works.

Orthopedic surgeon Dr. Vijay Borra doesnt do stem cell injections. He said he thinks research into stem cells just as an injection for osteoarthritis is still in its infancy.

I think a lot of research now is going into using stem cells to generate chondrocytes, which are cartilage to see if we can plug in focal cartilage deficits. Thats where all the research is now. As far as just injecting stem cells into the joint, were still at the very early stages and theres still very little data as to whether it actually works or not, Borra said.

Borra added that there is a lot of good data using that to generate cartilage.

Theres some data there can be used to plug defects. Its an option for people who have done everything like a steroid or hyaluronic gel injections. Theyve done all that and they dont want a knee replacement, or they have too many medical issues and theyre not a candidate. Then it is an option. If theres nothing else, then stem cell is an option, Borra said.

He added that stem cell therapy is not covered by most insurance plans and the out-of-pocket pay is very high.

Its really like an end-stage resort for someone who doesnt want surgery. Theres really no down side. Its not going to do any damage, so you can always try to see if it helps, Borra said.

When patients come to see him, Borra said he first gives them an x-ray to see what the problem is. Most of the time, its osteoarthritis.

By the time they come to Borra, he said the patient has tried anti-inflammatories, weight loss and therapy.

Theyve already done all that, so I start off with a steroid injection. If it works five, six months some people choose to do two or three a year. If it doesnt work, the next option is gel injections, hyaluronic acid, which is like artificial joint fluid, Borra said.

He said Othee also offers nerve blocks.

Link:
Odessa physician offering stem cell therapy - Odessa American

Garrett Richards is cleared to throw off a mound, still has a chance to return this season – Los Angeles Times

The Angels hope to insert Garrett Richards into their rotation this season, but they are up against time. Eight weeks remain in this season, and Richards should require roughly six weeks to ramp up his pitching. Any setback, and hell run out of wiggle room.

After three weeks of playing catch from increasing distances, Richards visited a team physician late Thursday, who cleared the right-hander to throw off of a mound Friday. It will be Richards first time pitching since April 5, and it will start the unofficial six-week timeline.

If Richards pitched out of the bullpen, he could conceivably return sooner. But the Angels are not considering that option.

No plan with that, Angels manager Mike Scioscia said. I think hes a starter. You are thinking about his career too. I think it would be the wrong move to put him in the pen and put more stress on his arm than hes used to.

Richards, 29, has not pitched out of the bullpen since 2013. When he first reached the majors in 2011, he flitted between starting and relieving. The Angels are confident he is best-suited to starting.

But he has started only seven of the Angels last 271 games, dating to last season. On May 1, 2016, he exited a game with what proved to be a torn ulnar collateral ligament in his elbow. Instead of surgery, he opted to undergo stem-cell injections, which doctors said healed the ligament over time.

After a normal offseason, he felt cramping in his first start of this season, on April 5 in Oakland. Later in the week, he was diagnosed with nerve irritation in his right biceps.

For more than three months, he waited, lifting weights and taking regular strength tests. When his right biceps finally measured nearly the same as his left, he began playing catch.

Since May, Richards has understood he would miss most of the season. But he has believed a September return was possible, and it still is.

Short hops

Left fielder Cameron Maybin (sprained knee) will begin a rehab assignment with triple-A Salt Lake on Friday. Hell play again Saturday and could be activated as soon as Monday. Right fielder Kole Calhoun (strained hamstring) ran the bases without issue before Thursdays game and plans to play Friday. Third baseman Yunel Escobar (back strain) is on a similar track. Right-hander Alex Meyer played catch for the first time in two weeks. He has been on the disabled list with shoulder inflammation he reported after his last start. Right-hander Matt Shoemaker will throw a second bullpen session Saturday. He felt fine Thursday after throwing the day before.

pedro.moura@latimes.com

Follow Pedro Moura on Twitter @pedromoura

More here:
Garrett Richards is cleared to throw off a mound, still has a chance to return this season - Los Angeles Times

How to Become a Regenerative Stem Cell Doctor

Overview

A new frontier in medicine, regenerative medicine or stem cell therapy involves the study of or the application of stem cells as a form of healing. Stem cells are naturally reproduced in the body therefore they are a renewable source of medicine with enormous potential. Still a relatively new area of scientific study, it is unknown just how far and wide reaching the healing capabilities of this type of therapy will be, but the potential seems quite limitless. A medical student choosing to specialize in this field of study will likely witness and participate in many new and exciting developments as this type of medicine evolves.

What is a Regenerative Stem Cell Doctor

A regenerative stem cell doctor is a specialist who uses stem cell therapy to treat patients. As this is still a comparatively new form of medicine, this type of doctor will likely be involved in research or clinical trials, discovering new treatments and their effects as well as preventative approaches based on cellular technology to treat currently unmanageable human diseases.

Stem cells generally fall under three categories:

A stem cell doctor may use this type of medical treatment with patients who suffer from autoimmune deficiencies or genetic blood diseases. It's also typical for stem cell doctors to focus on pharmaceutical product development in areas of systemic diseases, cardiac and vascular diseases, or orthopedic diseases of the spine or bone marrow transplantation outcomes.

A regenerative stem cell doctor may also be involved in cancer research through the use of stem cell medicine as an alternative to damaging treatments such as radiation and chemotherapy. Stem cell therapy is also currently being used to treat bone, skin and corneal diseases and injuries through tissue grafting.

Educational Requirements for Becoming a Regenerative Stem Cell Doctor

A doctoral or professional degree is the educational requirement for a Regenerative or Stem Cell Doctor

Falling under the category of medical scientist, a student wishing to become involved in the exciting field of cell-based regenerative medicine will find themselves at the forefront of the ground breaking evolution of medicine. Of course, the educational path to such an esteemed profession will require lifelong dedication to learning and continued research and may even require dual graduate degrees depending upon the student's individual goals; as well as a commitment to meeting challenges and the fortitude to deal with setbacks as this type of medicine evolves.

Step-by-Step Educational Path to Becoming a Regenerative Stem Cell Doctor

Bachelor's Degree

Holding an undergraduate degree from an accredited college is necessary in order to procure a place in medical school or to be accepted into a doctoral program. For those whose sights are set on eventually becoming a medical scientist and working in the field of regenerative stem cell medicine, it is ideal to begin with a strong background in biology, chemistry and biophysics. Majoring in life science, biology, microbiology or pre-med is a good starting point as well as taking writing classes as this field of study will require reporting, journaling and possibly public speaking at some point. Future medical students will need to take The Medical College Admissions Test (MCAT).

Volunteer

Volunteering is always a good idea and will make an impressive addition to any resume or application submitted towards attaining the candidate professional goals. Students interested in stem cell therapy may find volunteer opportunities at universities or laboratory environments as research assistants.

Internship

Students will gain hands on experience through an internship by working under the supervision of experienced stem cell researchers, assisting with current investigations, writing reports and sharpening other required skills in preparation for entering medical school or a doctoral program. Several internships can be applied toward college credit hours.

Masters Degree

A Master of Science Degree or a master's degree with a focusin stem cell biology and regenerative medicine will prepare the way for entry into medical or PhD programs. During this course of study the candidate will acquire an in depth understanding of how the body can naturally repair and restore damaged cells, tissues and organs through courses in cutting-edge biomedical sciences such as molecular, cellular, and developmental biology. These master's programs will also provide hands-on laboratory experience working with stem cells.

Doctoral Degree

Having a PhD in a biological sciences field is perhaps the final stepping stone to qualify for positions at the forefront of the exciting field of cell-based regenerative medicine. One must also obtain a doctorate in medicine if their intention is to administer stem cell treatments. Some schools offer dual degree programs and the candidate may pursue both MD and PhD degrees concurrently.

At this point the candidate learning how to become a stem cell doctor will evolve from education to application through translational science as they study and develop new therapies based on stem cell behavior. Future stem cell doctors will receive specialized training in subjects such as genetics and developmental biology, participate in laboratory-based stem cell courses, take advanced courses in stem cell biology and regenerative medicine, and gain experience through clinical rotations as well as producing original research in the form of a thesis or dissertation.

It is also typical during the doctoral degree program that a future doctor will focus on specialties such as law, business and/or engineering pertaining to stem cell research or focus on areas more relevant to physicians and surgeons.

Licensing

Medical students are required to pass the United States Medical License Exams (USMLE) and complete residency training as well as acquiring the appropriate state(s) licenses in order to practice medicine.

Post Graduate Residency

After becoming a licensed doctor, in order to practice medicine it is necessary to complete a residency program in the area of their chosen specialty. Doctors who wish to work in stem cell based therapies will most likely complete a residency in internal medicine and may want to focus on developing skills in oncology or hematology. However, research involving stem cell medicine bleeds over into many specialty domains.

Fellowship

Post-doctoral education and training may entail working with researchers and staff on projects involving gene therapy, organ engineering or microbial studies. The American Academy of Anti-Aging Medicine (A4M) is at the forefront of this area of education by being the world's first school to offer a Stem Cell Fellowship Program. Requirements include 5 modules of training and experience as well as completing the A4M Board Certification. More programs for this type of fellowship are being designed and implemented as awareness rises, advances continue, and more and more doctors and students are in need of resources specific to stem cell education and application.

Continuing Education

A select few graduates, post doctoral fellows and clinical fellows may be selected to participate in curriculum intended to develop leadership skills for applicants with the potential to become future independent scientists in stem cell research. The educational requirements for a future in stem cell medicine are never ending as the potential for new therapies continue to grow and evolve and new and exciting discoveries are made.

Practicing physicians and surgeons who specialize in stem cell therapies should become certified by The American Board of Stem Cell Medicine and Surgery (ABSCMS). Visit their website for more information.

Understanding the Career Path

Work Environments

The tentacles of stem cell research are far reaching. There are worldwide opportunities for professionals in this field and as new developments occur and are found to be effective and receive government approval, the doors of opportunity will continue to open. Most regenerative stem cell doctors will work full time in office or laboratory environments working with samples, studying data and creating or studying reports.

The U.S. Department of Labor lists the top industries employing medical scientistsincluding

Many practicing physicians perform stem cell related therapies that have not yet been approved by the FDA. Below are a few scenarios in which a stem cell scientist or stem cell doctor may find employment.

Universities

Opportunities in stem cell research and development abound and someone applying for these positions will find many opportunities in universities to include laboratory research as well as academic positions. A typical day may include working on the development of new treatments, working with samples, recording detailed reports involving studies and results, as well as writing and submitting grant proposals to gain additional funding for programs. Academic positions may include classroom instruction through texts, seminars or hands on training with students or writing publications regarding new discoveries as stem cell research uncovers new and exciting possibilities.

Hospitals

Doctors or medical scientists working in hospitals or hospital laboratories may work with individuals or groups of patients, administering treatments and monitoring the results during clinical trials. Surgeons specializing in stem cell therapies may work in hospitals with patients suffering from very specific conditions such as cancer patients and those with blood diseases. They will be involved in procedures such as bone marrow transplantation or the implantation of stem cells into the body to treat blood disorders such as lymphoma, leukemia, or sickle cell anemia. They may also perform surgeries involving tissue grafting for skin or corneal diseases and injuries.

Pharmaceutical Companies

Pharmaceutical companies are becoming more and more involved with stem cells as drug therapies as new experimental avenues are opened. Stem cell specialists may work with these companies combining stem cells with other pharmaceutical compounds in experimentation processes for the development of new therapeutics.

Salary Expectations

The median annual salary a stem cell doctor (medical scientists, except epidemiologists) can expect to earn, according to the U.S. Bureau of Labor Statistics, was $76,980 as of May 2012 with the highest ranking positions being compensated at over $146,000 and the lower 10% bringing in less than $42,000 annually. O Net reports the median wage (2014) to be equivalent to $38.43 hourly or $79,930 annually. This field of employment is expected to grow by 13% between 2012 and 2022.

Growth is expected to be driven by natural causes such as population growth and the continued spreading of infectious diseases which provide an ever increasing need for development in this field of medicine which can improve overall human health and create new cures for illnesses.

While becoming a regenerative or stem cell doctor isn't specific to any one medical specialty at this point, an interest in this field leaves many options for the beginning medical student. It's due to the relatively new nature of this field of study that candidates have several career options to explore. This profession has the potential to change lives, discover cures and provide higher quality medical care for billions of people living across the globe.

Read the original here:
How to Become a Regenerative Stem Cell Doctor

A Doctor’s View: Media has responsibility to spare us misleading advertising – Duluth News Tribune

The United States and New Zealand are the only countries in the world that allow such direct-to-consumer advertising. This means pharmaceutical companies can advertise their products directly to you via any media, whether radio, television, or newspapers.

This practice of direct-to-consumer advertising at one time was very heavily regulated by the U.S. Food and Drug Administration. That changed in 1997 when regulations regarding the listing of side effects were eased. In the decade that followed, spending for pharmaceutical advertising increased from $11 billion to $30 billion and has continued to boom in the last decade.

Why? Because its effective. Numerous studies show that direct-to-consumer advertising leads to the increased prescribing of expensive patented medicines rather than their generic alternatives and also leads to the increased use of off-label medicines.

I spend a lot of my time as a primary-care doctor talking through advertisements seen by patients. Common topics include that shingles shot, low testosterone, caloric supplements and multivitamins, and, recently, Hepatitis C screenings. To be clear, I love when my patients are informed, and I very much enjoy these conversations when the facts are clear. The problem, however, is, oftentimes, these advertisements lead to confusion and misinformation.

In mid-July I had a patient call my office near the end of the work day. He was frantic. He needed to get ahold of me immediately. He was at a stem cell education seminar and needed to know in the next few minutes if he should pay the thousands of dollars being requested for therapies that he was being told may help with his and his wifes chronic diseases. I told him no.

The following day we were sitting in my office and he showed me a full-page article in the News Tribune titled, Stem Cell Centers: Cutting Edge Treatments, Amazing Results. I call it an article because nowhere on the page did I see it labeled as an advertisement. The article instructed the reader, in all capital letters, to stop living with chronic pain. It wondered if you are a candidate and beckoned readers to a free seminar.

Per my patient, the seminar was exactly what you would expect: a made-for-TV advertisement offering to harvest the patient's stem cells and reinject them into the patient for the low price of $4,000 per injection. But wait, if you buy two, theres a $500 savings.

The truth about stem cells is that, while promising, they are largely unproven. That is, there is some very preliminary basic science research suggesting that stem cells may some day be beneficial in clinical medicine, but there are still no clinical trials that have shown any benefit. Nonetheless, companies stand to make a lot of money selling these uncertain therapies. States such as California and Florida are so fraught with stem cell clinics the FDA is weighing crackdowns. To be very clear, I would never advise a patient to undergo this treatment.

Physicians and medical societies, including the American Medical Association, have been calling for the FDA to crack down on direct-to-consumer advertising, as there is strong and mounting evidence that it leads to the increased costs of prescription medicines, the inappropriate off-label use of medicines, and, in some cases, the propagation of misinformation.

I suspect the FDA will make changes in the near future. In the meantime, our local news media has a responsibility here. There is an ethical and moral responsibility for the News Tribune to not let organizations like Stem Cell Centers prowl on our community.

The American Academy of Family Practice has recommendation guidelines for direct-to-consumer advertising: Advertisements must conform to applicable laws, including FDA and/or Federal Trade Commission guidelines (stem cell treatments are not FDA-approved); must be labeled as advertisements, unlike the ad in the News Tribune; should contain information that is accurate, balanced, objective, and complete, with no false or misleading statements; shouldnt promote unhealthy or unsafe practices; should mention risks if benefits are mentioned; and should not promote the use of products that have addictive or abuse potential.

Id urge the News Tribune to also insist that these advertisements recommend discussions with patients physicians. In the instance of Stem Cell Centers, my patient felt cornered and put on the spot for thousands of dollars.

Please, News Tribune, lets be partners in taking care of our communitys health.

Dr. Timothy Kufahl is a family physician in downtown Duluth.

Read more here:
A Doctor's View: Media has responsibility to spare us misleading advertising - Duluth News Tribune

The curious case of ClinicalTrials.gov, where dubious stem cell therapies seem legit – Ars Technica

Earlier this year, doctors reported the case of three women who went blind after having stem cells derived from their own fat injected directly into their eyeballsa procedure for which they each paid $5,000. Piecing together how those women came to pay for such a treatment, the doctors noted that at least one of the patients was lured by a trial listing on ClinicalTrials.gova site run by the US National Institutes of Health to register clinical trials. Though none of the women was ever enrolled in the trialwhich never took place and has since been withdrawnit was enough to make the treatment seem like part of legitimate, regulated clinical research.

At least 18 ostensible trials listed on the site offer similar stem cell treatments that participants must pay to receiveunlike most trials, which compensate rather than charge participants for experimental treatments. These trials, sponsored by seven companies total, claim to be developing therapies for a wide range of conditions, like erectile dysfunction, type II diabetes, vision problems, Parkinsons disease, premature ovarian failure, and chronic obstructive pulmonary disease (COPD). However, these trials are largely not backed by preliminary research. None of them has Food and Drug Administration approvaleven though the agency has published a draft guidance that suggests these treatments are subject to FDA regulation. And some of the studies are only granted ethical approval by review boards with apparent conflicts of interest and histories of reprimands from medical boards and the FDA.

Some of these studies, I mean, theyre just so outrageous, article author Leigh Turner, a bioethicist at the University of Minnesota, told Ars. But, to hook patients, a listing on ClinicalTrails.gov is helpful to stem cell clinics, he explains. A key thing that these businesses need to do is they need to look legitimate, they need to look credible, he explains. Listing studies on ClinicalTrials.gov is in some respects really clever from a marketing perspectiveand really dangerous.

Theyre taking a federally funded websitesupporting clinical research, he said, and using it as a marketing platform.

In his article Wednesday, Turner argued that the NIH should tighten restrictions on registering studies on the site. Right now, registration is largely based on the honor system. Its up to study sponsors to accurately note whether their study is subject to FDA regulation.

Some of these studies, I mean, theyre just sooutrageous

Many of the stem cell clinics argue that their work is not regulated by the FDA because theytreat each patient with the patient's own stem cells, called autologous-derived stem cells. In many cases, tissue is harvested from a patientoften fat tissue collected using liposuctionthen the tissue is processed in some way to obtain stem cells, which get injected back into the patient to treat any of several conditions. This was the case for the three blinded patients who received treatment at a clinic called US Stem Cell (previously known as Bioheart, Inc.).

Autologous treatments are exempt from FDA regulation if the cells are no more than minimally manipulated before they go back into the patient, the FDA noted to Ars. But a draft guidance that the agency has not yet enforced states that processing and isolating stem cells from tissue, specifically fat tissue, is not exempt. According to the draft guidance, this procedure involves cells that are more than minimally manipulated, because it alters the original relevant characteristics of the human tissue.

In a comment to Ars, the FDA said that, once the guidance is finalized, it will be able to apply the proper oversight to these stem cell treatments. In the meantime, it said:

We recognize that there are a number of clinics operating, which do not register with FDA. Consumers are encouraged to contact FDA and the appropriate state authorities in their jurisdictions to report any potentially illegal or harmful activity related to stem cell based products. We also encourage patients and health care providers to report adverse events associated with cellular therapies to FDA.

For now, stem cell clinics are skirting FDA oversight. Without enforcement, the only barrier to registering on ClinicalTrails.gov is to have an IRBinstitutional review boardsign off. These boards provide ethical oversight of a clinical trial and must be registered with the FDA.

See more here:
The curious case of ClinicalTrials.gov, where dubious stem cell therapies seem legit - Ars Technica

Doctors Used This Teen’s Own Cells to Cure Her Leukemiabut They Almost Killed Her First – Reader’s Digest

Courtesy Don CollinsEmma Collins was 14 when her parents began to notice something wasnt right with the typically energetic teen. Her father, Don Collins, tells Readers Digest: Emma was feeling tired and had very low energy at school. After a few days of noticing this, we had her blood tested. Collins continues, Later that night, the hematology lab called our house directly and told us to go to the hospital immediately. We took her in, and they confirmed our worst fear: Emma had leukemia. Emma was diagnosed with pre B acute lymphocytic leukemia (ALL), a fast growing form of leukemia that begins in the B cells of bone marrow. Approximately 80 to 85 percent of children diagnosed with ALL have a version that originates in B cells.

Shocked and heartbroken, Emma and her parents faced treatment options that included grueling rounds of chemotherapy. Collins recalls, Emmas treatment was three intensive rounds of chemotherapy, along with another medication called Sprycell. She was hospitalized at the Hospital for Sick Children in Toronto, Ontario for over six months. For the Collins, watching their daughter struggle to remain strong through the treatments was the most difficult.The lowest point for my wife and I was, seeing the gradual worsening of her health. She lost her hair, became unable to walk, and had constant infections that led to four ICU stays. She had very close calls with death, Collins explains. The Collins never gave up the belief that the next treatment would be successful, though their hopes were repeatedly dashed. Collins says, Of course, we kept hoping that the next round of chemotherapy would work, and when they all failed we were crushed. We were told that her chances of surviving another round of chemotherapy were extremely low, and it would likely yield the same negative results, he says. Patients with any cancer diagnosis should know these seven hopeful cancer statistics.

Left with no other viable chemotherapy treatment options, the Collins considered clinical trials. One of these trials was the CAR-T cell therapy, a new type of stem cell therapy with proven success in achieving remission for patients with leukemia. Doctors collect and then modify a patients own immune cells so that they recognize the cancer cells as an invader and mount a fight. Next, the modified cells are injected back into the patient to attack the cancerous cells. One serious drawback is that the treatment can also cause a potentially fatal immune reaction called cytokine release syndrome. While the reaction can be managed with medication, the patient can still feel lousy during treatment.

Courtesy Don CollinsDesperate to save their daughter, Collins and his wife agreed to try the CAR-T therapy. He says, With the news that all other treatment had failed, we kept up hope that this new treatment would help. Emma began to show signs of cytokine release syndrome only hours after the initial treatment; her fever spiked to 111 degrees, and she was nauseated. Her extremely elevated fever caused her to slip into a coma-like state, and she became unconscious for a short time, until doctors could stabilize her temperature.

Content continues below ad

A few days later, the Collins family received the stunning news: On the fourth day after treatment, the doctor came into our room and told us Emma was in full remission, Collins says. At first, it took a minute to sink inI was stunned but overcome with joy. We all sat together and laughed, cried, and went through all of the emotions that come with this kind of fantastic news. New medical developments are occurring at a fast pace with advancements in technology, and recent studies have also shown that good cholesterol, or HDL, can lower the risk of cancer.

Max Gomez, PhD, CBS News Medical Correspondent, and co-author of the upcoming book, Cells Are The New Cure, believes that cell therapy will be utilized in the future to treat many chronic conditions, like Alzheimers disease and type 1 diabetes. Cancer is only the beginning, Dr. Gomez told Readers Digest. We as humans have the hubris to think we can create drugs to heal peopleand we havebut weve got nothing on the human cell. According to Dr. Gomez, not only do the modified cells used in CAR-T therapy kill cancer cells during initial treatment, but they also create memory cells that continue to fight any cancerous cells that reappear once treatment has completed. This will completely change leukemia treatment for children and adultsand it already has, he says.

As for Emma, now 16, shes living the life her parents hoped she would. Shes doing great in remission, and has caught up in school, even achieving honor roll. She just received her drivers license, and she works out often to regain her balance and strength, something she lost from chemo, Collins says. He adds, Shes getting back to a normal teenagers life. Our greatest hope for Emma is to enjoy life and be happy and strong. We want her to look back on this and tell her grandchildren of the many great things she has achieved, including never losing hope and living through cancer. For patients that have reached remission there are several beneficial ways to care for yourself, mentally and physically after the cancer is gone.

Courtesy Don CollinsEmmas parents want other families facing a similar battle to know that though its new, trying CAR-T therapy can be worth the risk. He says, We absolutely encourage patients to proceed with this treatment. We know it can be scary as it is new, but we went from no hope to remission in four daysthat should give everyone hope. Hope means everything to a family going through a cancer diagnosis.

Go here to see the original:
Doctors Used This Teen's Own Cells to Cure Her Leukemiabut They Almost Killed Her First - Reader's Digest

These People Are Making Money Off A Bogus Cancer Cure That Doctors Say Could Poison You – BuzzFeed News

Apricot seeds can cure cancer or so thousands of cancer patients believed in the 1970s, despite lots of evidence to the contrary. Now, in an era when natural remedies are no longer fringe and wellness is a multitrillion-dollar industry, this widely debunked theory has taken on a new life as a hydra-headed e-commerce ecosystem that regulators are virtually powerless to stop.

Posted on July 30, 2017, 21:48 GMT

John Richardson thought hed found a cure for cancer.

The San Francisco Bay Area doctor had been giving patients a therapy that is essentially a chemical compound found in apricot kernels and known by several names laetrile, amygdalin, vitamin B17. Richardson had been told it could attack tumors, naturally and precisely. It can also convert into potentially poisonous amounts of cyanide when eaten. But Richardson was a true believer.

Yes, the evidence that Vitamin B17 is natures control for cancer is quite overwhelming, he wrote in his book. So the next time you hear an official spokesman for orthodox medicine proclaim that there is none, you might tell him that such a statement is a self-evident absurdity and suggest that he do his homework before posing as an expert.

Less convinced were the police who, on June 2, 1972, barged into Richardsons clinic and jailed him on charges of medical quackery. He eventually lost his medical license and was charged with smuggling laetrile, an illegal drug, into the country.

Now, three decades after Richardsons death, his son, John Richardson Jr., is no stranger to apricot seeds. Through Apricot Power, his thriving e-commerce store, he sells bitter seeds ($32.99 for 1,500), seed extract-based tablets (up to $97.99 a bottle), and B17-infused anti-aging cream ($49.99). Recipes for apricot-seed pesto, egg nog, and marzipan offer a delicious and easy way to work the supposed superfood into your diet, and videos explain why the sites mission is to get B17 into every body! Though Richardson Jr. wont reveal revenue numbers, he says his family operation of around 10 employees has served thousands of customers all over the world since it launched in 1999.

But theres a key difference between his business and his fathers, Richardson Jr. told me: We dont mention the C-word in our company. Cancer, that is. If a customer review on Apricot Powers website even mentions the term, the company leaves a comment pointing out that it doesnt make any disease or illness-related claims about its products. Legally, it cant: The FDA prohibits companies from selling laetrile, under any name, as a cancer treatment, because studies have found it to be at best ineffective, and at worst toxic.

Of course, that doesnt stop dozens of internet entrepreneurs from exploiting regulatory loopholes to sell apricot seeds and B17 tablets, no claims attached and profiting off the efforts of believers who spread the truth about them far and wide. In laetriles heyday in 1981, a doctor called it the slickest, most sophisticated, and certainly the most remunerative cancer quack promotion in medical history. Three decades later, the internet has only spread the gospel, creating an unstoppable, hydra-headed ecosystem of buyers and sellers.

A variety of apricot seed products available online.

If youve never heard that apricot kernels kill and prevent cancer, thats because the government doesnt want you to, proponents say. Cancer, according to them, arises from the lack of a nutrient they call vitamin B17, so it follows that ingesting that nutrient would fight the disease. But regulators, pharmaceutical companies, and doctors cant patent and profit from a natural substance. So they keep it off the market and peddle toxic, invasive, costly, and unnatural chemotherapy and drugs at patients expense.

The internet has created an unstoppable, hydra-headed ecosystem of B17 buyers and sellers.

Or so the theory goes. Vitamin B17 Is Banned Because It Treats Cancer! a post on the site Healthy Food House proclaims; it has been liked, commented on, and shared on Facebook more than 47,000 times since September, according to the social mediatracking tool CrowdTangle. A post about the real story of laetrile, published on a site called The Truth About Cancer, has gotten more than 44,000 likes, comments, and shares since June 2015.

Yin Ling Woo, a gynecological oncologist, recently had to decline when three cancer patients asked her to inject them with liquid B17 vials. They buy it off the internet, it arrives, they have to get someone to administer it, said Woo, who works in Kuala Lumpur, Malaysia.

Over the last year and a half, public health agencies in the European Union, Canada, and Dubai have issued warnings about apricot kernels and kernel-derived supplements. Since Australia and New Zealand outright blocked the sale of raw kernels in late 2015, retailers have been fined for continuing to sell them. In April, the FDA fired off warning letters to the sellers of more than 65 illegal cancer treatments, including whole apricots and vitamin B17. All the regulators cite the internet as the main source of the problem. Due to the nature of online marketing, some companies attempting to avoid compliance with FDA law simply start new websites and rename fraudulent products, an FDA spokesperson told BuzzFeed News in an email.

In other words, the FDA lacks the power to systematically fix the underlying issue. It can go after apricot kernels advertised as a cancer cure. But it cant crack down when theyre advertised as supplements or plain old seeds. Nor can it control the Facebook posts, YouTube videos, blogs, and tweets that perpetuate the myth.

And when the FDA calls out problematic claims, all a company has to do to escape scrutiny is stop using the phrases in question. But the misimpression that their product is an effective cancer cure will remain out there, uncorrected, in the public eye, said Patti Zettler, an associate professor at Georgia State Universitys law school and a former associate chief counsel at the FDA.

Its no coincidence that B17 is enjoying a second life online, at this moment in time. The internet is rife with misinformation about science and health, and the nutritional supplements business as part of the larger wellness industry is worth billions. Meanwhile, cancer remains a little understood disease that causes nearly 1 in 6 deaths worldwide. So in a way, its comforting and intuitive to blame a fixable vitamin deficiency. Its also wrong.

Felicity Corbin-Wheeler of Jersey, an island south of England, credits B17 injections and a strict diet with shrinking her pancreatic cancer in 2003. She refused chemotherapy, which aligns with her belief that the Western diet has been so hijacked by processed foods, sugars, fats, and salts.

Im all for the natural things, she said, that we get back to a simple life.

Ernst T. Krebs Jr., seen in San Francisco in 1980, was an early promoter of laetrile as a cancer treatment.

A successful salesperson must buy into what theyre selling, and Richardson Jr. is all in. Growing up in the Bay Area suburb of Orinda, he and his seven siblings werent fed sugar or processed wheat, an abstention he keeps up to this day. He says he started eating apricot seeds for his health at age 5. Now 52, hes up to 40 a day.

The seeds contain amygdalin, a compound also found in apple seeds and almonds. In the 1950s, Ernst T. Krebs Jr., a self-described doctor and biochemist with no medical degree, patented a purified form of amygdalin that he called laetrile. He also promoted it as vitamin B17, although its not an officially recognized vitamin.

In 1971, Krebs Jr. shared with the elder Richardson his theory of how this nutrient could stop cancer growth. As Richardson later summarized: [N]atures mechanism will not work if one fails to eat the foods that contain this necessary vitamin, which is exactly what has happened to modern man, whose food supply has become further and further removed from the natural state.

In Richardsons day, laetrilists were just as controversial as the anti-vaccine movement is today. In the 1960s, the FDA banned laetrile and reported that there was no evidence it treated cancer. But over the next decade, more than 70,000 Americans took it anyway. Many of them crossed into Mexico for injections denied by their stateside doctors. Actor Steve McQueen secretly traveled to Baja in 1980 to receive laetrile, among other alternative remedies, for an advanced lung cancer. He died months later. In the mid-70s, a scientist at Memorial Sloan Kettering Cancer Center performed experiments that he said showed laetrile helped reduce tumors in mice. A media relations staffer then leaked the data, claiming that hospital executives had sought to cover up and discredit it. Hes been making that claim ever since, including in the 2014 documentary Second Opinion (for the conspiracy-minded only, the Los Angeles Times wrote), and now charges cancer patients $500 for hourlong phone consultations.

In the mid-'70s, laetrilists were just as controversial as the anti-vaccine movement is today.

When the elder Richardson was arrested in 1972 (on charges that were dropped), it prompted his fellow members of the John Birch Society, the far-right conspiracist group of the era, to start a lobbying group to legalize laetrile. Later, Richardson was fined $20,000 and placed on probation on charges of conspiracy to smuggle laetrile from Mexico to the US. Indictments against him and 18 other accused promoters noted that he had deposited $2.5 million in his bank account over two years.

Even so, Richardson Jr. remembers his father, who died in 1988, as very principled, very honest, and very moral, and keeps a picture of him over his desk. Theres still people that contact me and tell me what a wonderful man he was and what a wonderful doctor he was, he said.

After long legal battles, the FDAs laetrile ban ultimately took effect in 1987. In 1999, Richardson Jr. started Apricot Power as an online-only store, but its branched out to health food shops over the last five years to meet customer demand. The company sources apricots from its farm and others in California, removes the flesh, air-dries the pits at the center, cracks them open, and sells the seeds inside.

A lot of the foods, the amygdalins been cooked out of it, said Richardson Jr., who also operates a real estate firm and a restaurant. And my dad believed a normal, healthy person should have 100 milligrams a day of amygdalin. Thats been our company motto since the beginning, is just getting amygdalin back into every body.

It took me no more than a few seconds to find apricot seeds online. A Google search led me to Amazon, where a European vendor was selling a 1-pound bag for $19.99 with this caveat: We do not treat, or aim to cure any disease. Still, its customers leave reviews like Raw Apricot Kernels help to stop Cancer in its tracks and I expect no miracles, but I dont want to die from chemotherapy. The seeds turned out to be chewy and tongue-curlingly bitter, with a long and unpleasant aftertaste.

Amazons algorithm recommended that I also buy the book thats the bible of this movement: World Without Cancer: The Story of Vitamin B17. First published in 1974 and now in its 24th printing, its by G. Edward Griffin, who has no scientific training, denies HIV, and pushes Sept. 11 conspiracy theories.

I tried to interview more than 35 e-commerce shops that sell seeds or supplements labeled as laetrile, amygdalin, or B17. Many declined to talk or never got back to me. A man at Raw Foods and Vitamins turned me down, explaining, The FDA and the government agencies have gone wild, theres so much money in Big Pharma. As soon as theres a little publicity, theyll be all over you. He did, however, text me pro-laetrile books and websites to look up.

Others were more open. Danny Hesman, who runs B17 USA full-time out of Los Angeles, said he has 5,000 repeat customers. I do tell people its not a magic pill, he said. But like some other vendors, hes had a personal experience with cancer in his case, a friend who died from it. I got a front-row seat to the suffering he went through with modern medicine, he said. I know these oncologists, I spoke to their team, they did everything. Its almost career suicide for professionals to even consider alternative therapies, which leaves [B17] in that fringe zone you see when you google vitamin B17. I wish there were some more professionals that would really work on that.

Many vendors, especially those in the US, repeatedly emphasized that they werent claiming to cure, treat, or prevent anything, as if the FDA were listening over the phone. But Our Fathers Farm in Ontario, Canada, sells kernels that may help with cancer prevention and symptoms. Vision B Seventeen in Kuala Lumpur, Malaysia, claims to have been successfully treating cancer and other degenerative diseases for more than 12 years now.

Regulators have tried to squash these kinds of vendors. Jason Vale, a professional arm wrestler in New York City, sold seeds as a cure on his website, Apricots From God, because he believed theyd healed his kidney cancer. He also spammed people with millions of email ads. But in 2003, Vale was sentenced to five years in prison for criminal contempt of a court injunction sought by the FDA to stop him selling.

Laetrile (i.e. Vitamin B17) therapy is one of the most popular and best known alternative cancer treatments.

B17 merchants may have been deterred by his conviction, but not defeated. Until recently, Oxygen Health Systems allegedly told customers, Laetrile (i.e. Vitamin B17) therapy is one of the most popular and best known alternative cancer treatments. This spring, the FDA slammed Oxygen with a warning letter for making that and other unsupported health claims. According to the agency, which sent similar warnings to 13 other businesses, Oxygen had also illegally described vitamin C, the fruit graviola, and flax seed oil as cancer therapies.

Owner Michael Carroll said by phone that many of his products personally helped him fight off non-Hodgkins lymphoma. He scrubbed the language targeted by the FDA. But he didnt seem too worried that his business would take a hit, or that his promises could have harmed someone.

Were continuing to work to make the best corrections to make our website as blah as possible, so consumers remain uneducated, said Carroll, who lives near Chicago. When we spoke in early May, Oxygen was still selling B17 bottles for up to $97; theyve since been taken down.

But you can still get them from Amygdalin Supply. Call to place an order and you might chat, as I did, with customer service rep Carlos Olguin in Guadalajara, Mexico. I asked him if, in his opinion, what he was selling could really treat cancer. His customers, he replied, were all the proof he needed.

If you go to a store and buy a product and the product doesnt work for you, would you buy again? he asked. Of course not, because the product does not work. Thats the thing I see. The same people who buy are the same people who are going to buy next and next and next.

Sandi Rog, a novelist outside Denver, Colorado, says that B17 saved her and can save others, too. She spreads the message on her blog, I Beat Cancer with Vitamin B17, and in three YouTube videos with a total of more than 956,000 views.

When Rog was diagnosed with non-Hodgkins T-cell lymphoma in late 2010, doctors put her through chemotherapy, radiation, and a stem cell transplant in an attempt to reinvigorate her immune system, she said. But tumors kept popping up. After a naturopathic doctor gave her dozens of supplements, she eventually narrowed them down to a regimen of juicing, pancreatic enzymes, and B17, which she began reading about and ordering online. She also stopped taking her prescribed immunosuppressant drugs. By the end of 2012, she said, the tumors were gone and she was in remission.

It makes me so angry, because people are being ripped off. "

All I know is Im cancer-free, she said, and its because of this.

Catherine Fox found Rogs videos very impressive when she started researching B17 as a preventative measure against cancer. Her parents, five aunts, and three uncles have all died of various cancers, she says. Then, about three years ago, she felt a lump in her breast the moment shed been dreading. So she started taking kernels. Thats likely why, she thinks, the lump ended up being harmless.

It seemed to just go down and go away, said Fox, who lives in Kells, Ireland, and, just to be safe, still eats two seeds every morning.

But Liz Beggs says that these stories offer a sense of false hope that harms people like her late niece, Charlene Campbell.

Campbell had a daughter who, not long after she was born, developed a rare, aggressive brain cancer and died. More than five years later, Campbell developed cancer, too, in her breast. Having watched her daughter undergo chemotherapy and radiation, she was determined to avoid them herself. So she started juicing, eating an all-vegetarian diet, and ordering cannabis oil and apricot seeds online. She said, This is my journey, its my body, I have to do it on my own, recalled Beggs, who lives in Northern Ireland. Youre either with me or against me.

Beggs understood why Campbell distrusted conventional therapies, but at the same time, we were so fearful, she said. Campbells tumor kept growing until she finally agreed to have a mastectomy. Then new tumors sprouted in her liver and spine.

Campbell died in October 2015, soon after her 33rd birthday. By the end, she was up to 40 apricot kernels a day, her aunt said.

It makes me so angry because people are being ripped off, Beggs said. That fear that engulfs a person when theyre diagnosed with cancer, they want to hold on to something thats positive, not the medical route. They want to hold on to this sick holistic path of believing in kernel seeds and whatever else across the internet.

Promoters of this all-natural cure cant agree on one name for it amygdalin, laetrile, Laetrile with a capital L, B17? Nor do they agree on how much to take and how often. Nor is there a way to ensure that the many seeds, pills, powders, and liquids in which it can take form are chemically consistent. All these variables make it hard to study its supposedly wondrous effects.

A 2015 review looked at the available studies of laetrile and amygdalin in humans and found no reliable evidence that they could cure cancer. On the whole, it concluded, the chances of bad side effects made the risks unambiguously negative.

In 1982, the Mayo Clinic put 178 cancer patients on laetrile, enzymes, vitamins, and a restricted diet, a regimen based on several laetrile doctors recommendations. When it came to getting cured, seeing their symptoms improve or disease stabilize, or living longer, they didnt substantially improve. On average, they survived less than five months after starting treatment.

I do remember some of the patients wanting it to be continued, believing it was working even though their tumor had clearly grown, they had gotten weaker and clearly more sick, said Gregory Sarna, a study co-author who was a UCLA oncologist at the time. That did not dissuade some of them from their belief that it was working.

Several patients also showed signs of poisoning, like nausea and vomiting, and blood levels of cyanide known to be fatal.

It doesnt take much. More than three small kernels, or less than half a large one, can be unsafe for adults, according to a report for the European Food Safety Authority. Even one small kernel can be toxic for toddlers. From 2000 to 2004, there were reports of 260 children poisoned by kernels in Turkey, where they are a common snack. One 2-year-old girl was severely poisoned and died after she ate 10 seeds. Laetrile fans, however, tend to promote much higher doses: One blogger cites World Without Cancers recommendation of 3 to 5 seeds per waking hour to treat cancer, and 7 to 10 a day to prevent it.

None of these contradictions faze consumers, who say scientists and doctors design studies to fail. They question whether people have really gotten sick or died from apricot kernels and if they did, they probably took way too much. (I never had a bad experience, said Elif Ercanli, who grew up eating seeds in Istanbul, Turkey.) The most theyll admit to is a bad side effect here or there. Rog said she once took nine in a 12-hour span and my blood pressure crashed so low, I was in bed, I had tingling in my fingers and toes.

When I asked people to explain how amygdalin works, they paraphrased, or told me to look up, World Without Cancer. According to Griffin, when amygdalin dissolves in body fluids and produces hydrogen cyanide, the cyanide only goes after cancer cells because of a special enzyme they contain thats vulnerable to attack.

That explanation doesnt make sense to Sarna, who is now an oncologist at Cedars-Sinai Medical Center. He points out that cancer cells differ even within a single tumor which is usually why when a treatment destroys some cells, others remain untouched. To say [one enzyme] is a general characteristic of cancer would need a study of hundreds of thousands of fresh cancers, all different cancers, he said. Ive never seen that done.

Theres no doctor in the world who doesnt want to help their patient get better. I never quite understood why theres this conspiracy theory that doctors or pharmaceutical companies would have an interest in suppressing something that works."

Even if there were one magical mechanism that unlocked the cure to cancer, Wendy Chen, a breast oncologist at Dana-Farber Cancer Institute, takes offense at the notion that physicians would cover it up.

Theres no doctor in the world who doesnt want to help their patient get better, she said. I never quite understood why theres this common conspiracy theory that doctors or pharmaceutical companies would have an interest in hiding or suppressing something that works.

Nevertheless, Griffins theories still light up Facebook groups like Cancer! Is B17 the cure? Brandon Clark, who says apricot seeds and B17 tablets got rid of a skin cancer on his nose, moderates the 3,000-person group. When he started contributing, he read B17 books and talked to B17-prescribing doctors to make sure people had the best information possible. Clark, who lives near Tacoma, Washington, prefers to share that research on Facebook because its much more popular than Twitter and Myspace and anything else, he said. I felt like I could reach more people.

Hes not wrong.

Theyre preying on people who are vulnerable and ill, Beggs said of people like Clark. Its just so not right. It makes me angry. Theyre being brainwashed. Charlenes proof of that.

The bottom of Apricot Power's Ground SuperFood Mix.

Apricot kernel devotees are fond of a certain Bible verse, Genesis 1:29: Then God said, I give you every seed-bearing plant on the face of the whole earth and every tree that has fruit with seed in it. They will be yours for food. There is an intuitive appeal to this implicit idea, that a higher force designed a natural substance to fight off a devastating and inexplicable disease.

Cancer kills 1 in 4 men and 1 in 5 women in the US. And surgery, chemotherapy, and radiation can sound frightening on their own, since they involve cutting open the body and flooding it with drugs and X-rays. The side effects range from unpleasant to downright unbearable.

Theyre preying on people who are vulnerable and ill. Its just so not right. It makes me angry. Theyre being brainwashed."

So there has always been an appetite, to some degree, for alternative therapies. And because of the enormous power of placebos, people often do feel better after taking them. In 1979, when the Supreme Court ruled that terminally ill cancer patients did not have the right to access laetrile, it noted that entrepreneurs had long hawked cancer cures like liniments of turpentine, mustard, oil, eggs, and ammonia; peat moss; arrangements of colored floodlamps; pastes made from glycerin and limburger cheese; mineral tablets; and Fountain of Youth mixtures of spices, oil, and suet.

But in 2017, once-fringe natural remedies are no longer distinct from the mainstream obsession with wellness, now a $3.7 trillion industry spanning organic food, yoga, meditation apps, anti-aging lotions and dietary supplements. Lifestyle guru Gwyneth Paltrow and alt-right fearmonger Alex Jones peddle silver nanoparticles and obscure mushrooms. In addition to being taken by 150 million people in the US, supplements are barely regulated, can contain anything, arent proven to help health, and send at least 20,000 Americans to the emergency room annually.

The fact there is a resurgence of interest in selling and utilization of what is essentially an ineffective treatment is concerning, and it points to general problems with the supplement market, said Ameet Sarpatwari, an instructor at Harvard Medical School, of B17. The amount of money being spent out there in supplements is huge. You would think that it should be more well-regulated than it is.

The wellness industrial complex is built upon vague pronouncements and falsehoods about how nutrition and bodies work, like the (unsupported) myth that genetically modified food is unsafe to eat. But if you buy into that, then perhaps its not so crazy to also believe that, say, the Hunza, an indigenous group in northern Pakistan, are cancer-free thanks to their apricot-heavy diet. (According to anthropologists, there are no credible studies to support the claim, which is central to the B17 ideology.)

The fact there is a resurgence of interest in selling and utilization of what is essentially an ineffective treatment is concerning, and it points to general problems with the supplement market.

As the internet breathes new life into health myths, it complicates the relationship between patients and doctors. No longer are physicians the main or exclusive source of medical information when people can Google a remedy, buy it on Amazon, and tell their Facebook friends about it.

So when cancer patients get excited about laetrile, or any other alternative therapy, doctors must balance the evidence, or lack thereof, with the desperation of people often on the verge of death. People need control over something that they cannot control, and that is very, very frustrating, and I sense it with every person I treat, said Don Dizon, clinical co-director of gynecologic oncology at Massachusetts General Hospital Cancer Center and a spokesperson for the American Society of Clinical Oncology.

Natural, though, does not mean safe. Toxins, cyanide included, abound in the natural world. All that matters is what are the benefits and harms, what is known for certain and what is merely unknown, said Vinay Prasad, a hematologist-oncologist at Oregon Health and Science University, by email.

One patient of Prasads wanted to try high doses of vitamin C, but resisted radiation therapy because it seemed unnatural. Of course, Prasad noted, both vitamin C and radiation are naturally occurring, and both high dose [vitamin C] and a radiation machine are a human manipulation of something natural, so I wasnt sure there is a difference.

Dizon isnt always confident that chemotherapy will work, particularly in people whose cancer has returned, so he encourages some of them to push back. Hes even seen some tumors shrink after patients have taken natural remedies and hes accepted that he cant explain why. Sometimes, doctors say, a person may not actually have cancer in the first place, due to an incorrect diagnosis or misinterpreted biopsy. Or tumors can shrink due to other therapies that a patient has forgotten about or hasnt revealed.

Regardless, a couple moving anecdotes arent license to recommend an unproven remedy. That would be wrong, because thats not data, Dizon said. Thats not the same thing as saying, Your mom has ovarian cancer. If shes taking treatment, she has a 30% chance of cure and an 80% chance of going quite some time, even maybe years, before her cancer comes back.

With alternative therapies, the success stories that people cling to tend to be more isolated than they think. Youre not hearing the other side of that the patients who took it and died within weeks or whose cancers really grew, he said.

Vitamin B17, by any name, will never disappear. Its story by now has taken on mythical proportions that cannot be censored.

New advances in cancer treatment may one day make apricot seeds obsolete. But until even if all these therapies become the new and highly successful standard of care, some segment of laetrile believers will continue to buy in.

At Apricot Power, Richardson Jr. is busy rolling out products such as chocolate bars with chopped-up apricot seeds. (What a tasty way to get natural B17 in your diet! the website proclaims.)

What would his father think of all this? Hed be happy, Richardson Jr. answered, because he predicted that someday people would discover that nutrition was the answer to healthy living. He added, Lots of people believe an ounce of prevention is worth a pound of cure.

Stephanie Lee is a senior technology reporter for BuzzFeed News and is based in San Francisco.

Contact Stephanie M. Lee at stephanie.lee@buzzfeed.com.

Got a confidential tip? Submit it here.

News moves fast. Keep up with the BuzzFeed News daily email!

Great!

You're almost there! Check your inbox and confirm your subscription now!

See the original post here:
These People Are Making Money Off A Bogus Cancer Cure That Doctors Say Could Poison You - BuzzFeed News

Cell-Based Therapies in MS Remain Experimental, Expert Group Argues in Review Article – Multiple Sclerosis News Today

Clinical trials are the way to explore whether cell-based therapies are viable options for treating multiple sclerosis, a group of experts concluded in a publication exploring the state of research in the field.

The article, Cell-based therapeutic strategies for multiple sclerosis, was the result of discussions held at the International Conference on Cell-Based Therapy for Multiple Sclerosis in 2015. The experts reviewed evidence on a range of cell therapies, including stem cell transplants and delivery or stimulation of various cell types.

Clinical trials, the panel argued, would be the optimal way to examine which types of cells should be used, how they should be delivered, and the types and disease stages the treatments are suitable for.

The article, published in the journal Brain, focused on four types of cell-based treatments: autologous stem cell transplants, mesenchymal and related stem cell transplants, use of drugs to manipulate stem cells in the body to boost their ability to repair, and transplants of oligodendrocyte progenitor cells to trigger new myelin production. Loss of the myelin that protects neurons is a hallmark of MS.

Such treatments hold promise to attain what current disease-modifying therapies in MS have not: halting the disease without lifelong treatment that has potential side effects, and regenerating damaged tissue.

The International Conference on Cell-Based Therapy for Multiple Sclerosis was sponsored by the National MS Society which brought attention to the review in a news release and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Although plenty of research continues, there are issues that need to be resolved in order to steer the research in a healthy direction.

For instance, studies of autologous stem cell transplants have used an array of protocols and approaches.This makes it difficult to compare study results. The expert group said stem cell research would be better performed by networks of scientists who have agreed on a standard protocol.

Researchers also need to determine how to measure whether a stem cell therapy is working and how to monitor patients for safety.

For each approach, it is also necessary to determine which patients are likely to benefit from the treatment evidence that is currently only available for autologous stem cell transplants.

In addition to reviewing the evidence surrounding cell-based treatments, the expert group focused on the availability of the treatment options outside controlled trials.

Media attention has resulted in some cases of misrepresentation and exaggeration of therapeutic claims for cell-based therapies for multiple sclerosis and other diseases, the team wrote.

This has caused patients to seek the treatments paying out-of-pocket at unregulated clinics.

Often such clinics are for obvious reasons based in jurisdictions with less stringent medical regulatory structures, and so there can often be little if any assurance of the expertise, quality of care (or even hygiene), or ethical standards of the provider centre, which is often unwilling or unable to seek more traditional financial support for their research, they wrote.

Such clinics should at least confirm that the procedure is carried out by staff with appropriate qualifications, training, and experience. The clinic, and the treating physician, should also offer a written treatment plan, which should mention how complications will be monitored and managed, the team argued.

By far the most well-researched cell-based treatment option in MS is autologous stem cell transplants. The treatment, based on isolating a patients own blood or bone marrow stem cells, is combined with chemotherapy to wipe out the patients currently defective immune system. Once the immune system is eradicated, doctors transplant a patients stem cells back into the body to reboot the system.

The new stem cells give rise to a new population of immune cells, which if the treatment works do not causethe autoimmune properties characteristic ofMS.

While evidence suggests the treatment may be highly efficient in certain patients, it is not clear how it compares with other treatments that are considered highly effective.

The use of chemotherapy to eradicate a patients immune system brings with it risk of death. The experts, led by Dr. Neil Scolding ofSouthmead Hospital Bristol in the United Kingdom, noted that while procedures have become safer in recent years, risk remains the main argument against the treatment.

Patients with MS typically live for decades after a diagnosis, so any therapy with significant risk of mortality will not readily be accepted, the team wrote.

To evaluate the risk-efficiency profile of the treatment, a multi-center Phase 3 trial is needed to compare stem cell transplants with approved highly effective drugs.

Evidence is clear about who might benefit from such a treatment, the team wrote. Patients with active relapsing-remitting MS who are relatively young, with a disease duration of less than five years, are good candidates for the procedure, particularly if they do not respond to other treatment, evidence indicates.

In contrast, it is unlikely that autologous stem cell transplants will benefit patients with a long disease history or those who have progressive MS without recent inflammatory activity, they argued.

In an effort to improve the gathering of evidence supporting the treatment, they suggested that physicians who perform transplants outside the scope of clinical trials should collect data on the treatments safety and effectiveness andsubmit itto registries.

In addition, transplants should be performed at centers with MS expertise that are experienced in the procedure, the experts recommended.

Researchers have increasingly focused on mesenchymal stem cells power to treat various conditions, including MS. These cells are found in several adult tissues, including fat,umbilical cord blood, and bone marrow.

In contrast with the autologous stem cell transplant procedure, the use of mesenchymal stem cells does not involve chemotherapy. The idea is rather that the cell therapy should trigger the bodys own regenerative processes to repair damaged tissue.

To start the procedure, doctors isolate cells from a patient, grow them in a lab in a process that gets rid of other cell types, and inject them back into the patient. The injection can either be intravenous or through a spinal tap to inject cells into the central nervous system.

So far, there have only been small clinical trials of the procedure in MS patients. And researchers have yet to optimize the source or dose of cells that should be used, or the best method to grow and re-inject the cells into patients.

Several larger Phase 2 trials are underway, however, the team noted. These trials may clarify whether the treatment is effective in treating MS, and reveal which patients are likely to benefit.

In the central nervous system, myelin is produced by glial cells called oligodendrocytes. Researchers believe it may be possible to regenerate myelin by transplanting stem cells destined to become oligodendrocytes.

But the expert panel noted that there is evidence suggesting that it is not a lack of such cells that prevents remyelination. Rather, the absence of necessary factors in the body or the presence of inhibitory factors might be at work, they suggested.

Since MS involves damage not only to myelin, but also to nerve cell axons the long cell projections that send signals outward from a neuron it is also relevant to find out whether damaged axons can be remyelinated, they argued.

Moreover, researchers are unsure of how to prove that remyelination actually occurs in MS patients exposed to the therapy.

The U.S. Food and Drug Administration recently approved such an approach to be tested in patients.

Although this approach differs from the others the panel reviewed because it does not involve the handling of cells, it deserves mention.

The panel noted that several drugs in development, including opicinumab, are aimed at promoting remyelination. In addition, drugs that are already approved for other conditions might have remyelinating properties, and might be repurposed to treat MS.

Although studies are ongoing, the panel noted that it is unclear if the drugs do promote remyelination.

Despite ongoing research and in some cases clinical use of cell-based therapies for MS, these treatments should be considered experimental, the expert group concluded.

They again underscored the importance of clinical trials in providing a controlled environment for patients wishing to have cell therapy, as well as a source of evidence for the feasibility of these approaches.

Read the original:
Cell-Based Therapies in MS Remain Experimental, Expert Group Argues in Review Article - Multiple Sclerosis News Today

High-tech solutions top the list in the fight against eye disease – Engadget

Cataracts are the single leading cause of blindness worldwide, afflicting roughly 42 percent of the global population, including more than 22 million Americans. The disease, which causes cloudy patches to form on the eye's normally clear lens, can require surgery if left untreated. That's why Google's DeepMind AI division has teamed with the UK's National Health Service (NHS) and Moorfields Eye Hospital to train a neural network that will help doctors diagnose early stage cataracts.

The neural network is being trained on a million anonymized optical coherence tomography (OCT) scans (think of a sonogram, but using light instead of sound waves) in the hopes it will eventually be able to supplement human doctors' analyses, increasing both the efficiency and accuracy of individual diagnoses.

"OCT has totally revolutionized the field of ophthalmology. It's an imaging system for translucent structures that utilizes coherent light," Dr. Julie Schallhorn, an assistant professor of ophthalmology at UC San Francisco, said. "It was first described in 1998 and it gives near-cell resolution of the cornea, retina and optic nerve.

"The optic nerve is only about 200 microns thick, but you can see every cell in it. It's given us a much-improved understanding of the pathogenesis of diseases and also their response to treatments." The new iteration of OCT also measures the phase-shift of refracted light, allowing doctors to resolve images down to the capillary level and observe the internal structures in unprecedented detail.

"We're great at correcting refractive errors in the eyes so we can give you good vision far away pretty reliably, or up close pretty reliably," Schallhorn continued. "But the act of shifting focus from distance to near requires different optical powers inside the eye. The way the eye handles this when you're young is through a process called 'accommodation.'" There's a muscle that contracts and changes the shape of the lens to help you focus on close objects. When you get older, even before you typically develop cataracts, the lens will stiffen and reduce the eye's ability to change its shape.

"The lenses that we have been putting in during cataract surgery are not able to mimic that [shapeshifting] ability, so people have to wind up wearing reading glasses," Schallhorn said. There's a lot of work in the field to find solutions for this issue and help restore the eye's accommodation.

There are two front-runners for that: Accommodating lenses, which use the same ciliary muscle to shift focus, and multifocal lenses, which work just like your parents' multifocal reading glasses except that they sit directly on the eye itself. The multifocals have been on the market for about a decade, though their design and construction has been refined over that time.

To ensure the lenses that doctors are implanting are just as accurate as the diseased ones they're removing, surgeons are beginning to use optiwave refractive analysis. Traditionally, doctors relied on measurements taken before the surgery to know how to shape the replacement lenses and combined those with nomograms to estimate how powerful the new lens should be.

The key word there is "estimate." "They especially have problems in patients who have already had refractive surgery like LASIK," Schallhorn explained. The ORA system, however, performs a wavefront measurement of the cornea after the cataract has been removed to help surgeons more accurately pick the right replacement lens for the job.

Corneal inlays are also being used. These devices resemble miniature contact lenses but sit in a pocket on the cornea that's been etched out with a LASIK laser to mimic the process of accommodation and provide a greater depth of focus. They essentially serve the same function as camera apertures. The Kamra lens from AcuFocus and the Raindrop Near Vision Inlay from Revision Optics are the only inlays approved by the FDA for use in the US.

Glaucoma afflicts more than 70 million people annually. This disease causes fluid pressure within the eye to gradually increase, eventually damaging the optic nerve that carries electrical signals from the eye to the brain. Normally, detecting the early stages of glaucoma requires a comprehensive eye exam by a trained medical professional -- folks who are often in short supply in rural and underserved communities. However, the Cambridge Consultants' Viewi headset allows anyone to diagnose the disease -- so long as they have a smartphone and 10 minutes to spare.

The Viewi works much like the Daydream View, wherein the phone provides the processing power for a VR headset shell -- except, of course, that instead of watching 360 degree YouTube videos, the screen displays the flashing light patterns used to test for glaucoma. The results are reportedly good enough to share with you eye doctor and take only about five minutes per eye. Best of all, the procedure costs only about $25, which makes it ideal for use in developing nations.

And while there is no known cure for glaucoma, a team of researchers from Stanford University may soon have one. Last July, the team managed to partially restore the vision of mice suffering from a glaucoma-like condition.

Normally, when light hits your eye, specialized cells in the retina convert that light into electrical signals. These signals are then transmitted via retinal ganglion cells, whose long appendages run along the optic nerve and spread out to various parts of the brain's visual-processing bits. But if the optic nerve or the ganglion cells have been damaged through injury or illness, they stay damaged. They won't just grow back like your olfactory sensory nerve.

However, the Stanford team found that subjecting mice to a few weeks of high-contrast visual stimulation after giving them drugs to reactivate the mTOR pathway, which has been shown to instigate new growth in ganglion cells, resulted in "substantial numbers" of new axons. The results are promising, though the team will need to further boost the rate and scope of axon growth before the technique can be applied to humans.

Researchers from Japan have recently taken this idea of cajoling the retina into healing itself and applied it to age-related macular degeneration cases. AMD primarily affects people aged 60 and over (hence the name). It slowly kills cells in the macula, the part of the eye that processes sharp detail, and causes the central focal point of their field of vision to deteriorate, leaving only the peripheral.

The research team from Kyoto University and the RIKEN Center for Developmental Biology first took a skin sample from a human donor, then converted it into induced pluripotent stem (IPS) cells. These IPS cells are effectively blank slates and can be coerced into redeveloping into any kind of cell you need. By injecting these cells into the back of the patient's eye, they should regrow into retinal cells.

In March of this year, the team implanted a batch of these cells into a Japanese sexagenarian who suffers from AMD in the hope that the stem cells would take hold and halt, if not begin to reverse, the damage to his macula. The team has not yet been able to measure the efficacy of this treatment but, should it work out, the researchers will look into creating a stem-cell bank where patients could immediately obtain IPS cells for their treatment rather than wait months for donor samples to be converted.

And while there isn't a reliable treatment for dry-AMD, wherein fatty protein deposits damage the Bruchs membrane, a potent solution for wet-AMD, which involves blood leaking into the eyeball, has been discovered in a most unlikely place: cancer medication. "Genentech started developing a new drug when an ophthalmologist in Florida just decided to inject the commercially available drug into patients eyes," Schallhorn explained.

"Generally this is not a great idea because sometimes things will go terribly wrong," she continued, "but this worked super-well. It basically stops and reverses the growth of these blood vessels." The only problem is that the drugs don't last, requiring patients to receive injections into their eyeballs every four to eight weeks. Genentech and other pharma companies are working to reformulate the drug -- or at least develop a mechanical "reservoir" -- so it has to be injected only once or twice a year.

Stem-cell treatments like those used in the Kyoto University trial have already proved potentially effective against a wide range of genomic diseases, so why shouldn't it work on the rare genetic condition known as choroideremia? This disease is caused by a single faulty gene and primarily affects young men. Similar to AMD, choroideremia causes light-sensitive cells at the back of the eye to slowly wither and die, resulting in partial to complete blindness.

In April of 2016, a team of researchers from Oxford University performed an experimental surgery on a 24-year-old man suffering from the disease. They first injected a small amount of liquid into the back of the eye to lift a section of the retina away from the interior cellular wall. The team then injected functional copies of the gene into that same cavity, replacing the faulty copies and not only halting the process of cellular death but actually restoring a bit of the patient's vision.

Gene therapy may be "surely the most efficient way of treating a disease," lead author of the study, Oxford professor Robert MacLaren, told BBC News, but its widespread use is still a number of years away. Until then, good old-fashioned gadgetry will have to suffice. Take the Argus II, for example.

The Argus II bionic eye from Second Sight has been in circulation since 2013, when the FDA approved its use in treating retinitis pigmentosa. It has since gotten the go-ahead for use with AMD in 2015. The system leverages a wireless implant which sits on the retina and receives image data from an external camera that's mounted on a pair of glasses. The implant converts that data into an electrical signal which stimulates the remaining retinal cells to generate a visual image.

The Argus isn't the only implantable eyepiece. French startup Pixium Vision developed a similar system, the IRIS II, back in 2015 and implanted it in a person last November after receiving clearance from the European Union. The company is already in talks with the FDA to bring its IRIS II successor, a miniaturized wireless subretinal photovoltaic implant called PRIMA, to US clinical trials by the end of this year.

Ultimately, the goal is to be able to replace a damaged or diseased eye entirely, if necessary, using a robotic prosthetic. However, there are still a number of technological hurdles that must be overcome before that happens, as Schallhorn explained.

"The big thing that's holding us back from a fully functional artificial eye is that we need to find a way to interface with the optic nerve and the brain in a way that we transmit signals," she said. "That's the same problem we're facing with prosthetic limbs right now. But there are a lot of smart people in the field working on that, and I'm sure they'll come up with something soon."

Continue reading here:
High-tech solutions top the list in the fight against eye disease - Engadget